OverviewSuggest Edit

LogicBio Therapeutics, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect.

TypePublic
Founded2014
HQLexington, MA, US
Websitelogicbio.com

Latest Updates

Employees (est.) (Dec 2019)41(+79%)
Job Openings8
Revenue (FY, 2020)$3.5 M
Share Price (Jul 2021)$4.3
Cybersecurity ratingAMore

Key People/Management at LogicBio Therapeutics

Frederic Chereau

Frederic Chereau

Board Member
Fred Chereau

Fred Chereau

President and Chief Executive Officer
Mariana Nacht

Mariana Nacht

Chief Scientific Officer
Cecilia Jones

Cecilia Jones

Chief Financial Officer
Marie Payton

Marie Payton

VP, Clinical Operations
Carol Sherako

Carol Sherako

VP, Program Management
Show more

LogicBio Therapeutics Office Locations

LogicBio Therapeutics has an office in Lexington
Lexington, MA, US (HQ)
65 Hayden Ave
Show all (1)

LogicBio Therapeutics Financials and Metrics

LogicBio Therapeutics Revenue

LogicBio Therapeutics's revenue was reported to be $3.45 m in FY, 2020
USD

Revenue (Q1, 2021)

461.0k

Net income (Q1, 2021)

(10.3m)

EBIT (Q1, 2021)

(10.0m)

Market capitalization (29-Jul-2021)

137.0m

Closing stock price (29-Jul-2021)

4.3

Cash (31-Mar-2021)

63.9m

EV

83.1m
LogicBio Therapeutics's current market capitalization is $137 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

3.5m

General and administrative expense

1.4m2.3m6.9m10.4m12.2m

R&D expense

2.0m3.6m11.1m30.7m22.8m

Operating expense total

3.4m5.9m17.9m41.0m35.0m
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

1.0m965.0k461.0k

General and administrative expense

470.0k2.1m2.6m2.5m2.2m3.2m3.0m4.1m

R&D expense

580.0k2.4m5.5m7.9m8.9m7.2m5.9m6.4m

Operating expense total

1.1m4.6m8.1m10.5m11.0m10.4m8.9m10.5m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

1.7m24.6m80.9m33.1m70.1m

Accounts Receivable

263.0k

Prepaid Expenses

86.0k1.1m1.3m2.0m2.2m

Current Assets

1.8m25.7m82.2m52.8m72.5m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

12.9m27.9m25.5m38.7m43.2m36.7m63.9m

Accounts Receivable

89.0k

Prepaid Expenses

1.7m1.8m2.0m1.6m3.0m1.9m2.1m

Current Assets

14.6m74.3m65.8m64.9m46.3m38.6m66.1m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(3.4m)(5.8m)(17.6m)(40.1m)(32.6m)

Depreciation and Amortization

16.0k43.0k89.0k289.0k475.0k

Accounts Payable

340.0k771.0k35.0k(527.0k)(177.0k)

Cash From Operating Activities

(2.4m)(5.8m)(15.3m)(38.7m)(28.9m)
Quarterly
USDQ2, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(1.7m)(5.9m)(10.6m)(7.7m)(17.7m)(28.7m)(9.5m)(17.7m)(10.3m)

Depreciation and Amortization

42.0k39.0k49.0k39.0k104.0k189.0k105.0k226.0k138.0k

Accounts Payable

369.0k(273.0k)(570.0k)201.0k448.0k779.0k1.6m(113.0k)262.0k

Cash From Operating Activities

(1.3m)(6.3m)(10.6m)(8.2m)(17.0m)(27.0m)(7.5m)(15.8m)(8.1m)
USDFY, 2016

Financial Leverage

1.8 x
Show all financial metrics

LogicBio Therapeutics Operating Metrics

Q2, 2018

Trademarks

2
Show all operating metrics

LogicBio Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

LogicBio Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

LogicBio Therapeutics Online and Social Media Presence

Embed Graph

LogicBio Therapeutics News and Updates

LogicBio Therapeutics Reports First Quarter Year 2021 Financial Results and Provides Business Update

LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today...

Cecilia Jones Joins LogicBio Therapeutics as Chief Financial Officer

LEXINGTON, Mass., Dec. 22, 2020 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced the appointment of Cecilia Jones as the Company's chief financial officer, effective January 11, 2021. Matthias Jaffe, the current CFO at...

LogicBio Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

- IND for LB-001 in methylmalonic acidemia (MMA) cleared in August 2020, with first patient in Phase 1/2 SUNRISE trial expected to be enrolled in early 2021- Fast Track designation for LB-001 in MMA received in November 2020- First follow-on offering post-IPO closed in October 2020

LogicBio Therapeutics Announces Pricing of Public Offering of Common Stock

LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the pricing of its previously announced underwritten public offering…

LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients

– LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform –

LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates

FDA Clears IND Application for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients FDA Clears IND Application for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients
Show more

LogicBio Therapeutics Blogs

LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021

LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021 Content Import Thu, 07/08/2021 - 07:02 LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021 July 8, 2021 at 7:00 AM EDT This release is a backfil…

LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia

- Company believes dosing represents first in vivo gene editing therapy delivered systemically to a pediatric patient - Clinical trial designed to treat patients as young as 6 months old with LB-001 based on proprietary GeneRide™ platform - Company remains on track to announce update on enrollment,

LogicBio Therapeutics to Participate in Upcoming Investor Conferences

LEXINGTON, Mass. , June 1, 2021 /PRNewswire/ --  LogicBio Therapeutics, Inc.  (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau ,

LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments

- Stephen Boyer joined company as vice president, regulatory and quality affairs and Peter Pechan joined as vice president, gene therapy LEXINGTON, Mass. , May 19, 2021 /PRNewswire/ --  LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and

LogicBio Therapeutics Strengthens Management Team with Key Appointments

- New leadership includes Andrea Paul as general counsel and corporate secretary, and Janice Olson as senior vice president, strategy and portfolio management, bringing extensive experience in gene therapy and rare disease LEXINGTON, Mass. , May 10, 2021 /PRNewswire/ --  LogicBio Therapeutics, Inc.

LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia

- Data presented at ACMG meeting evaluate disease progression in non-transplanted patients and children receiving liver transplantation LEXINGTON, Mass. , May 3, 2021 /PRNewswire/ --  LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and
Show more

LogicBio Therapeutics Frequently Asked Questions

  • When was LogicBio Therapeutics founded?

    LogicBio Therapeutics was founded in 2014.

  • Who are LogicBio Therapeutics key executives?

    LogicBio Therapeutics's key executives are Frederic Chereau, Fred Chereau and Mariana Nacht.

  • How many employees does LogicBio Therapeutics have?

    LogicBio Therapeutics has 41 employees.

  • What is LogicBio Therapeutics revenue?

    Latest LogicBio Therapeutics annual revenue is $3.5 m.

  • What is LogicBio Therapeutics revenue per employee?

    Latest LogicBio Therapeutics revenue per employee is $84.2 k.

  • Who are LogicBio Therapeutics competitors?

    Competitors of LogicBio Therapeutics include Immunocore, Agenus and Aruvant.

  • Where is LogicBio Therapeutics headquarters?

    LogicBio Therapeutics headquarters is located at 65 Hayden Ave, Lexington.

  • Where are LogicBio Therapeutics offices?

    LogicBio Therapeutics has an office in Lexington.

  • How many offices does LogicBio Therapeutics have?

    LogicBio Therapeutics has 1 office.